The Bayer Group continued its positive business momentum in the third quarter of 2013 with substantial contributions from the Life Science, Healthcare and CropScience sectors.
"Healthcare registered encouraging growth, largely due to the outstanding sales performance for our new pharmaceutical products," said Bayer Management Board Chairman, Dr. Marijn Dekkers.
After currency and portfolio adjustments, reported sales of the Bayer Group grew by 6.0%. Earnings before interest and tax improved by a substantial 47.5% to EUR 1,221 million. Gross cash flow moved ahead by 35.9% to EUR 1,367 million, mainly as a result of the significant improvement in EBIT. Net cash flow fell by 13.0% to EUR 1,728 million because less working capital was released than in the prior-year quarter. Net financial debt declined from EUR 9.0 billion on June 30, 2013 to EUR 7.7 billion on Sept. 30, 2013, largely as a result of cash inflows from operating activities.
For the full report, visit BAYER INVESTOR RELATIONS
No comments:
Post a Comment